HomeCompareMEDXF vs VICI

MEDXF vs VICI: Dividend Comparison 2026

MEDXF yields 89.29% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEDXF wins by $1.52M in total portfolio value
10 years
MEDXF
MEDXF
● Live price
89.29%
Share price
$2.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.49M
Annual income
$776,963.67
Full MEDXF calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — MEDXF vs VICI

📍 MEDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEDXFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEDXF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MEDXF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDXF
Annual income on $10K today (after 15% tax)
$7,589.29/yr
After 10yr DRIP, annual income (after tax)
$660,419.12/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, MEDXF beats the other by $144,149.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDXF + VICI for your $10,000?

MEDXF: 50%VICI: 50%
100% VICI50/50100% MEDXF
Portfolio after 10yr
$1.73M
Annual income
$692,169.89/yr
Blended yield
40.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

MEDXF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.9
Piotroski
5/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDXF buys
0
VICI buys
0
No recent congressional trades found for MEDXF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEDXFVICI
Forward yield89.29%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$2.49M$966.2K
Annual income after 10y$776,963.67$607,376.13
Total dividends collected$2.19M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: MEDXF vs VICI ($10,000, DRIP)

YearMEDXF PortfolioMEDXF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$19,629$8,928.57$11,361$941.49+$8.3KMEDXF
2$37,382$16,378.98$13,320$1,481.32+$24.1KMEDXF
3$69,150$29,152.23$16,284$2,405.01+$52.9KMEDXF
4$124,390$50,399.46$21,040$4,071.78+$103.3KMEDXF
5$217,827$84,729.38$29,209$7,285.49+$188.6KMEDXF
6$371,743$138,667.67$44,443$14,006.51+$327.3KMEDXF
7$618,933$221,167.77$75,822$29,512.55+$543.1KMEDXF
8$1,006,401$344,142.93$148,733$69,726.75+$857.7KMEDXF
9$1,599,826$522,977.14$344,394$189,413.75+$1.26MMEDXF
10$2,488,777$776,963.67$966,234$607,376.13+$1.52MMEDXF

MEDXF vs VICI: Complete Analysis 2026

MEDXFStock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Full MEDXF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this MEDXF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDXF vs SCHDMEDXF vs JEPIMEDXF vs OMEDXF vs KOMEDXF vs MAINMEDXF vs NNNMEDXF vs EPRTMEDXF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.